Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China

被引：0
作者：
Huang, Kun [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Pediat, Sch Med, 1367 Wenyi West Rd, Hangzhou 311121, Zhejiang, Peoples R China
来源：
ADVANCES IN THERAPY | 2024年 / 41卷 / 04期
关键词：
Hemophilia A; Pharmacokinetics; Cost-effectiveness; Prophylaxis; Bleeding;
D O I：
10.1007/s12325-024-02786-0
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：1759 / 1761
页数：3
相关论文
共 50 条
[41]   Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK [J].
Narayan, Omendra ;
Bentley, Anthony ;
Mowbray, Katie ;
Hermansson, Monika ;
Pivonka, Dominic ;
Kemadjou, Eric Ngonga ;
Belsey, Jonathan .
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) :1640-1652
[42]   Treatment for Severe Lupus Nephritis: A Cost-Effectiveness Analysis in China [J].
Dai, Zonglin ;
Zhang, Xi ;
Wong, Irene Ol ;
Lau, Eric H. Y. ;
Lin, Zhiming .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[43]   Application of a Value Framework to Determine the Value of Prophylaxis Versus On-Demand Treatment in Adults with Hemophilia A in China [J].
Tan, Baoying ;
Lin, Ailing ;
Han, Rong ;
Bai, Lu ;
Sun, Jing ;
Hu, Shanlian ;
Xuan, Jianwei .
ADVANCES IN THERAPY, 2025, 42 (04) :1881-1891
[44]   Cost-Effectiveness of Topical Prophylaxis Against Tympanostomy Tube Otorrhea: An Economic Decision Analysis [J].
Conner, Grant ;
Yoshiyasu, Yuki ;
Rossi, Nicholas ;
McKinnon, Brian .
OTO OPEN, 2024, 8 (03)
[45]   Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden [J].
Neovius, Kristian ;
Buesch, Katharina ;
Sandstrom, Kristina ;
Neovius, Martin .
ACTA PAEDIATRICA, 2011, 100 (10) :1306-1314
[46]   Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation [J].
Vanness, DJ ;
Kim, WR .
HEALTH ECONOMICS, 2002, 11 (06) :551-566
[47]   Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States [J].
Bullement, Ash ;
Knowles, Emma S. ;
DasMahapatra, Pronabesh ;
Ali, Talaha ;
Preblick, Ron .
PHARMACOECONOMICS-OPEN, 2021, 5 (04) :625-633
[48]   Simultaneous bilateral total knee arthroplasty in severe hemophilia: A retrospective cost-effectiveness analysis [J].
Thes, A. ;
Molina, V. ;
Lambert, T. .
ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH, 2015, 101 (02) :147-150
[49]   Lamivudine Compared With Newer Antivirals for Prophylaxis of Hepatitis B Core Antibody Positive Livers: A Cost-Effectiveness Analysis [J].
Wright, A. J. ;
Fishman, J. A. ;
Chung, R. T. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 (03) :629-634
[50]   Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective [J].
Alsumali, Adnan ;
Chemaly, Roy F. ;
Graham, Jonathan ;
Jiang, Yiling ;
Merchant, Sanjay ;
Miles, LaStella ;
Schelfhout, Jonathan ;
Yang, Joe ;
Tang, Yuexin .
JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (06) :3786-3794
12345